Basic Research Progress and Prospect of Antibody-Drug Conjugate in Treatment of Pancreatic Cancer
10.3971/j.issn.1000-8578.2025.25.0293
- VernacularTitle:抗体偶联药物治疗胰腺癌的基础研究进展及展望
- Author:
Juying JIAO
1
;
Lei ZHOU
1
;
Bo LIN
1
;
Jingyi ZENG
1
;
Weijie XU
1
Author Information
1. Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
- Publication Type:REVIEWS
- Keywords:
Pancreatic cancer;
Antibody-drug conjugate;
Basic research
- From:
Cancer Research on Prevention and Treatment
2025;52(9):787-791
- CountryChina
- Language:Chinese
-
Abstract:
Most patients with pancreatic cancer are already in the locally advanced or metastatic stage at initial diagnosis. While systemic chemotherapy provides clinical benefits for those with mid-to-late-stage pancreatic cancer, its efficacy is often limited by patient tolerance. In response to the dual clinical demands of robust antitumor activity and high targeting specificity, antibody-drug conjugate (ADC) has emerged as a promising solution. By conjugating highly selective monoclonal antibodies with potent cytotoxic small-molecule drugs, ADC achieves precise tumor-targeting while minimizing damage to healthy tissues, which thereby improves treatment tolerance. However, due to the complex pathological features of pancreatic cancer, no ADC has yet been approved for clinical use for this disease. A comprehensive evaluation of factors including ADC-specific targets, payload selection, antibody-drug linkage strategies, drug delivery mechanisms, tissue distribution variability, and tumor heterogeneity will be crucial to advancing the clinical translation of ADC for pancreatic cancer treatment.
